{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T00:43:35Z","timestamp":1791852215086,"version":"4.3.4"},"reference-count":18,"publisher":"American Society for Microbiology","issue":"4","license":[{"start":{"date-parts":[[2012,4,1]],"date-time":"2012-04-01T00:00:00Z","timestamp":1333238400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["J Clin Microbiol"],"published-print":{"date-parts":[[2012,4]]},"abstract":"ABSTRACT<\/jats:title>\n \n The M.I.C. Evaluator strip (Thermo Fisher Scientific, Basingstoke, United Kingdom) uses a methodology similar to that of Etest. In this first assessment of the M.I.C. Evaluator device, 409 strains of aerobic Gram-positive bacteria (staphylococci, streptococci, and enterococci) and 325 strains of\n Enterobacteriaceae<\/jats:named-content>\n ,\n Pseudomonas<\/jats:named-content>\n species, and\n Acinetobacter<\/jats:named-content>\n species were tested by M.I.C. Evaluator strip, Etest, and broth microdilution as a reference standard. The Gram-positive bacteria included staphylococci (methicillin-resistant\n Staphylococcus aureus<\/jats:named-content>\n , methicillin-susceptible\n S. aureus<\/jats:named-content>\n , and coagulase-negative staphylococci),\n Streptococcus pneumoniae<\/jats:named-content>\n , beta-hemolytic streptococci and viridians group strains, vancomycin-resistant enterococci, and other enterococci. The Gram-negative bacteria included 250 strains of 60\n Enterobacteriaceae<\/jats:named-content>\n species plus 50\n Pseudomonas<\/jats:named-content>\n and 25\n Acinetobacter<\/jats:named-content>\n species. A total of 14 antimicrobial agents (depending on the species) were included. The same methodology and reading format were used for M.I.C. Evaluator strips and Etest. Broth microdilution methodology was performed according to CLSI document M07-A8. For the clinical strains, >95% of results were plus or minus one doubling dilution for all species. There were fewer than 5% minor errors, fewer than 3% major errors, and fewer than 1% very major errors. M.I.C. Evaluator strips and Etest often reported higher MICs than the reference broth microdilution method. The M.I.C. Evaluator strips provided results comparable to those of the predicate Etest device and are of value for the accurate testing of MICs for these important pathogens.\n <\/jats:p>","DOI":"10.1128\/jcm.05395-11","type":"journal-article","created":{"date-parts":[[2012,1,12]],"date-time":"2012-01-12T05:19:18Z","timestamp":1326345558000},"page":"1147-1152","update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":17,"title":["First Comprehensive Evaluation of the M.I.C. Evaluator Device Compared to Etest and CLSI Broth Microdilution for MIC Testing of Aerobic Gram-Positive and Gram-Negative Bacterial Species"],"prefix":"10.1128","volume":"50","author":[{"given":"R. P.","family":"Rennie","sequence":"first","affiliation":[{"name":"Medical Microbiology Research Laboratory, Department of Laboratory Medicine and Pathology, University of Alberta Hospital, Edmonton, Alberta, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Turnbull","sequence":"additional","affiliation":[{"name":"Medical Microbiology Research Laboratory, Department of Laboratory Medicine and Pathology, University of Alberta Hospital, Edmonton, Alberta, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Brosnikoff","sequence":"additional","affiliation":[{"name":"Medical Microbiology Research Laboratory, Department of Laboratory Medicine and Pathology, University of Alberta Hospital, Edmonton, Alberta, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Cloke","sequence":"additional","affiliation":[{"name":"Thermo Fisher Scientific, Basingstoke, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkr065"},{"key":"e_1_3_2_3_2","unstructured":"Clinical and Laboratory Standards Institute. 2009. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard 8th ed. M07-A8. CLSI Wayne PA."},{"key":"e_1_3_2_4_2","unstructured":"Clinical and Laboratory Standards Institute. 2011. Performance standards for antimicrobial susceptibility testing: twenty-first informational supplement. M100\u2013S21. CLSI Wayne PA."},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2004.12.003"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2334-10-72"},{"key":"e_1_3_2_7_2","first-page":"28","article-title":"Investigation of the susceptibilities of extended-spectrum beta-lactamase producing Escherichia coli and Klebsiella spp. strains to ertapenem and other carbapenems","volume":"45","author":"Kuzucu C","year":"2011","unstructured":"KuzucuC YetkinF GorgecS ErsoyY. 2011. Investigation of the susceptibilities of extended-spectrum beta-lactamase producing Escherichia coli and Klebsiella spp. strains to ertapenem and other carbapenems. Mikrobiyol. Bul. 45:28\u201335.","journal-title":"Mikrobiyol. Bul."},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01406-06"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkq206"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.5858\/2006-130-767-PAOAAA"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.00637-08"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.05397-11"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/48.4.493"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.41.1.351-358.2003"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.36.4.1020-1027.1998"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9343(96)00105-2"},{"key":"e_1_3_2_17_2","unstructured":"U.S. Food and Drug Administration. 2007. Class II special controls guidance document: antimicrobial susceptibility test (AST) systems; guidance for industry and FDA. FDA Rockville MD."},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1469-0691.2010.03299.x"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/0732-8893(94)90058-2"}],"container-title":["Journal of Clinical Microbiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/JCM.05395-11","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/JCM.05395-11","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,5]],"date-time":"2022-03-05T11:12:22Z","timestamp":1646478742000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/JCM.05395-11"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,4]]},"references-count":18,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2012,4]]}},"alternative-id":["10.1128\/JCM.05395-11"],"URL":"https:\/\/doi.org\/10.1128\/jcm.05395-11","relation":{},"ISSN":["0095-1137","1098-660X"],"issn-type":[{"value":"0095-1137","type":"print"},{"value":"1098-660X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,4]]},"assertion":[{"value":"2011-09-16","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2012-01-03","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2012-03-16","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}